EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study

Dennis M McNamara iD, Leslie T Cooper, Matthias G Friedrich, Yaron Arbel, Arvind Bhimaraj, Edimar Bocchi, Andrew Hamer, Artur Haddad Herdy, Mathieu Kerneis iD, Peter P Liu, Andrea B Parker, Stuart J Pocock iD und 5 weitere

ESC Heart Failure · 03.02.2026 · 13 (1)

DOI: 10.1093/eschf/xvaf034 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, online erschienen am 16.01.2026. Verfasst von Dennis M McNamara und 16 weiteren Autor:innen. Beteiligte Einrichtung: Heart and Vascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA. Hauptthemen laut MEDLINE: Myocarditis, Cannabidiol, Ventricular Function, Left, Stroke Volume. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cardiol Therapeutics Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cannabidiol has been shown to exert significant anti-inflammatory effects and has demonstrated efficacy in murine models of autoimmune myocarditis, pericarditis, and heart failure. The ARCHER Study assessed whether a pharmaceutically produced cannabidiol formulation showed beneficial effects on cardiac magnetic resonance (CMR) endpoints known to predict prognosis in this patient population.

Methods

In a multicentre international double-blind placebo-controlled phase 2 study, we randomly assigned 109 patients within 10 days of CMR confirmed diagnosis of acute myocarditis to 12 weeks of pharmaceutically produced oral cannabidiol (active) or placebo. Dose was titrated up to 10 mg/kg of body weight twice daily. Primary endpoints were the difference in extracellular volume (ECV) and global longitudinal strain (GLS) measured by CMR at week 12. Other CMR endpoints included left-ventricular ejection fraction (LVEF), LV mass, intracellular volume (ICV), LV end-diastolic and end-systolic volumes (LVEDV, LVESV), and left-atrial end-systolic volume (LAESV).

Results

All randomized patients (56 active/53 placebo) completed the study with no loss to follow-up. Study drug appeared safe and well tolerated. Baseline mean ECV 38.9 ± 10.9 ml, GLS −15.3 ± 3.6%, and LVEF 60.6 ± 9.9% were consistent with mild to moderate myocarditis and predominantly intact LV function. Week 12 mean ECV was 33.6 ml in the active group and 37.3 ml in the placebo group, a difference of −3.7 ml, confidence interval (CI): −7.4 to 0.1; P = .0538; GLS was −16.0% in the active group and −15.9% in the placebo group, difference of −0.1, CI: −1.2 to 1.1; P = .90. Left ventricular mass was significantly reduced in the active group at 121.1 g compared to placebo 130.3 g, a difference of −9.2, CI: −16.4 to −2.1; P = .0117. In terms of remodelling, LAESV was significantly reduced in the active group (−8.1 ml; P = .0376) while the reduction in LVEDV failed to reach significance (−7.4 ml; P = .098).

Conclusion

In mild-to-moderate acute myocarditis, treatment with pharmaceutically manufactured cannabidiol was not associated with a statistically significant change in myocardial ECV or GLS, although a trend towards reduction in ECV was observed. In addition, improvement in other potential markers of myocardial recovery, including a significant reduction in LV mass, was seen in the active treatment group. Further investigation of the therapeutic potential of this therapy in inflammatory cardiac conditions is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisCannabidiolVentricular Function, LeftStroke VolumeRecovery of FunctionMyocardiumHumansFemaleMaleMagnetic Resonance Imaging, CineDouble-Blind MethodAcute DiseaseAdultGlobal Longitudinal StrainTreatment OutcomeFollow-Up StudiesMiddle AgedDose-Response Relationship, Drug

Stichwörter der Autor:innen

Anti-inflammatoryCMRCannabidiolMyocarditisRandomized trial

Substanzen

Cannabidiol

Autor:innen und Institutionen

  • Heart and Vascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Jacksonville, FL, USA.
  • Departments of Medicine and Diagnostic Radiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada.
  • Department of Cardiology, Universitätsklinikum Heidelberg, Heidelberg, Germany.
  • Departments of Cardiac Sciences and Radiology, University of Calgary, Calgary, AB, Canada.
  • Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Dennis M McNamara, Mathieu Kerneis, Stuart J Pocock

Förderung

  • Cardiol Therapeutics Inc.

Zitieren

APA

McNamara, D. M., Cooper, L. T., Friedrich, M. G., Arbel, Y., Bhimaraj, A., Bocchi, E., Hamer, A., Herdy, A. H., Kerneis, M., Liu, P. P., Parker, A. B., Pocock, S. J., Smith, E. R., Tang, W. H. W., Torre-Amione, G., Tschöpe, C., & ARCHER Study Group (2026). Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study. ESC Heart Failure, 13(1). https://doi.org/10.1093/eschf/xvaf034

Vancouver

McNamara DM, Cooper LT, Friedrich MG, Arbel Y, Bhimaraj A, Bocchi E, et al. Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study. ESC Heart Failure. 2026;13(1). doi:10.1093/eschf/xvaf034

BibTeX
@article{McNamara2026,
  author = {McNamara, Dennis M and Cooper, Leslie T and Friedrich, Matthias G and Arbel, Yaron and Bhimaraj, Arvind and Bocchi, Edimar and Hamer, Andrew and Herdy, Artur Haddad and Kerneis, Mathieu and Liu, Peter P and Parker, Andrea B and Pocock, Stuart J and Smith, Eldon R and Tang, W H Wilson and Torre-Amione, Guillermo and Tschöpe, Carsten and ARCHER Study Group, ARCHER Study Group},
  title = {Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study},
  journal = {ESC Heart Failure},
  year = {2026},
  volume = {13},
  number = {1},
  doi = {10.1093/eschf/xvaf034}
}
Kostenlos starten →